Medicine News

Orforglipron added to NHS dm+d 8.4.0 — event medicine guidance

Orforglipron: a new GLP-1 receptor agonist in the dm+d

The NHS Business Services Authority has added orforglipron to the dm+d dictionary (version 8.4.0). Orforglipron is a GLP-1 receptor agonist — a class of injectable medication used to improve blood glucose control in type 2 diabetes.

What is orforglipron used for?

Orforglipron is prescribed to improve glycaemic control in type 2 diabetes mellitus. It is administered as a subcutaneous injection once weekly, typically starting at 0.5 mg and titrated to 1 mg based on response. It works by stimulating insulin secretion in response to blood glucose levels.

Event medicine relevance

Orforglipron is unlikely to require acute administration at events, but you may encounter attendees already taking it. The key event-medicine concern is hypoglycaemia risk — especially if the person is also taking insulin or sulphonylureas, or is in a hot environment with increased physical activity.

Be aware that nausea is a common side effect and may be mistaken for other causes of gastrointestinal upset. If an attendee reports severe abdominal pain shortly after injection or during the event, consider acute pancreatitis and escalate to hospital. Convey any signs of severe allergic reaction (rash, angioedema, difficulty breathing) immediately.

Key cautions and interactions

  • Hypoglycaemia: Risk is higher if co-prescribed with insulin or sulphonylureas; monitor blood glucose and be ready with glucose if needed.
  • Renal function: Avoid in severe renal impairment (eGFR <15); dehydration increases acute kidney injury risk — monitor hydration status at events.
  • Pancreatitis history: Use with caution; severe abdominal pain warrants hospital referral.
  • Alcohol: May potentiate hypoglycaemia risk.
  • Oral anticoagulants: GLP-1 agonists may increase anticoagulant effect; monitor INR if relevant.
  • Contraindicated: Personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2.

Further information

For full prescribing details, consult the BNF or NHS Medicines A-Z.

View the full dm+d entry via the NHS BSA dm+d dictionary.